Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings
June 06, 2023 09:05 ET
|
Paratek Pharmaceuticals
Transaction Provides Paratek Shareholders with Immediate Value and Liquidity Reflects Potential Value of $3.00 per Share of Common Stock, Including Upfront Cash Payment of $2.15 per Share and a...
Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million
May 09, 2023 16:05 ET
|
Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of...
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
May 01, 2023 08:30 ET
|
Paratek Pharmaceuticals
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30...
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023
April 10, 2023 07:30 ET
|
Paratek Pharmaceuticals
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
March 16, 2023 07:30 ET
|
Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year -- Continued Progress on the Rare Disease Nontuberculous...
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
March 08, 2023 08:30 ET
|
Paratek Pharmaceuticals
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16,...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 01, 2023 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 01, 2023 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)
January 18, 2023 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV)...
Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract
January 05, 2023 08:00 ET
|
Paratek Pharmaceuticals
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of...